Despite this, the consistent enrichment of key oncogenic pathways—such as PI3K/AKT and MAPK signaling—in both the original and randomized settings support their centrality in cancer progression and aligns with the transcription factor disruptions identified in the pancreatic cancer subnetwork. This evidence concerns the gene AKT1 and familial pancreatic carcinoma.